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Abstract: Dexamethasone sodium phosphate
(DSP) is the most common corticosteroid
used in the treatment of edema paired with
brain tumors (1, 2). As with other
corticosteroids, DSP has some adverse
effects on the cardiovascular, immune and
nervous systems. The objective of this study
was to minimize the adverse effects of DSP
and to extend the release time of the drug
from microspheres by encapsulating with
Bovine Serum Albumin (BSA). The
microspheres were prepared by emulsion
polymerization. An aqueous solution of
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Introduction
Microparticulate carriers provide the localization of
the drug at the site of action, lower the concentration of
the drug and as a result reduce the side effects and
increase patient compliance. Microspheres, that are
monolytic microcarriers, can easily achieve the targetting
of the drug to the site of action and the localization of the
drug (1).
The blood-brain barrier (BBB), provides a control
system that regulates the transport of the materials
which is also affected by physical, humoral and nerval
changes. The BBB is present in all vertebrate brains and
is laid down within the first trimester of human fetal life
(2). Despite the endothelium in the peripheral tissues, in
the cerebrovascular endothelium there is no
phenestration that allows the transport of the solute and
the solvent but tight junctions exist. These tight junctions
are as tight as any in biology and the electrical resistance
across intraparenchymal endothelial cells may be as high
as 8000 ohm-cm2 (3); in this way the BBB has an
important role in providing a stabile extracellular
environment in the central nervous system (4).
The degree of transporting of the drugs through the
BBB depends on the solubility of the drug in lipids. The

glutaraldehyde (25% w/v) was used as the
crosslinking agent in two different amounts.
The release time DSP was found to be
extended in the series containing 15% DSP
with the increase in the amount of
glutaraldehyde used. Also it was observed
that the release time is extended in series
prepared using 0.5 mL glutaraldehyde with
the amount of DSP.
Key Words: Dexamethasone Sodium
Phosphate, BSA Microspheres, In vitro
Evaluation.

other factors are the molecular weight, the charge of the
drug and the capability of binding to proteins (5).
Dexamethasone sodium phosphate (DSP) is a white or
slightly yellow crystalline powder. 1.3 mg of DSP is nearly
equivalent to 1 mg of Dexamethasone. (DSP) is a
corticosteroid which is widely used in the treatment of
edema associated with brain tumors (6, 7). For the
treatment of these cases, biodegradable PLGA implants
are prepared and in vitro dissolution profiles are
investigated. The release time of these implants were
found to be 193 days. As with the other corticosteroids,
DSP has some adverse effects on the immune, nervous
and cardiovascular systems. In the treatment of edema
generally an initial high dose of DSP is applied followed by
lower doses (8).
The two most important factors in choosing the most
suitable polymer are the biodegradibility and the toxicity
of the polymer. The polymer BSA (Bovine Serum
Albumin) is biodegradable and non-toxic and it was
chosen for the preparation of the microspheres.
The aim of this study was to reduce the side effects of
DSP and to extend the release time using natural and
synthetic polymers. In order to extend the release time of
DSP, two different crosslinking times (30 min/60 min)
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and two different quantities of glutaraldehyde (0.5
mL/0.75 mL) were used. The amounts of DSP were
chosen as 5% and 15%.
Materials and Methods
Materials
DSP was purchased from Deva Holding A.Ş.; and the
polymer was from the Armour Pharmaceutical Company.
As the crosslinking agent, 25% aqueous solution of
glutaraldehyde (Merck) was used.
Methods

Preparation
Microspheres containing DSP were prepared by
emulsion polymerization (9, 10). 0.125 g of BSA was
dissolved id distilled water and mixed with 100 mL of
cotton seed oil. The homogenous mixture was added to
100 mL cotton seed oil continuously stirred at 1400 rpm
and 25°C. The resulting microspheres were washed with
diethyl ether (anhydrous) to remove the oil phase and the
microspheres were stabilized using 0.5 mL and 0.75mL
glutaraldehyde solution (25% w/v) for 30 min. and 60
min. Afterwards the microspheres were dried in a vacuum
oven overnight and stored at + 4°C.

Determination of Encapsulation Efficiency
10 mL of pH7.4 phopshate buffer was added to
accurately weighed 10 mg of DSP microspheres and this
mixture was kept in an ultrasonic bath. After
centrifugation, the supernatant was filtered through a
0.45µm filter and absorbance was read at λ=242 nm.
After drying, the residue was mixed with 5mL 0.1N
glacial acetic acid and stored at + 4°C for one night. Later,
it was centrifuged at 5000 rpm and the absorbance of
the supernatant was read at λ=242 nm after filtration
through a 0.45µm filter.

Surface Morphology
SEM examination of the microspheres was carried out
to study the surface morphology. Microspheres were
mounted on metal stubs with conductive silver paint and
then sputtered with a 150 A° thick layer of gold in a
BIORAD apparatus. A scanning electron microscope (JeolSEM ASID-10 Device in 80 KV) was used to evaluate the
surface characteristics of the microspheres.

In vitro Release
The in vitro release profiles of BSA microspheres
containing DSP were investigated in pH 7.4 buffer
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solution. Weighed amounts of microspheres were
suspended in 25 mL of buffer solution at 35 ± 0.5 °C in
horizontally shaken flasks. 1 mL samples were with
withdrawn and the appropriate volume fresh medium
was added at regular time intervals. The amount of DSP
released was calculated from the UV absorption
measurements of samples at λ=242 nm.

Particle Size
The particle size distribution of BSA microspheres
containing DSP were obtained with a Malvern Mastersizer
(Malvern Inst., UK). Size analysis was performed after
suspending the microspheres in an isotone solution
containing 0.01% (w/v) Tween 80.
Results and Discussion
As seen in Figure 1 the surface of the BSA
microspheres were found to be very smooth and the
microspheres were spherical, but just after the release of
the DSP was completed the smooth surface and the
spherical outline were lost.
The particle size distribution, synthesis efficiency and
encapsulation efficiency of the microspheres are given in
Table 1.
The microspheres crosslinked using 0.5 mL
glutaraldehyde showed an extension in the release time of
DSP directly proportional with the increase in the amount
of DSP. On the other hand, microspheres crosslinked
using 0.75 mL glutaraldehyde showed an opposing
profile and the release time of DSP decreased while DSP
amount increased. When the series containing the same
amount of DSP were compared, the release time of DSP
was increased with the increasing amount of
glutaraldehyde.
In the series containing 5% and 15% DSP, an
extension in the release time of DSP was not observed for
any of the eight series as the crosslinking time is
increased, but in the series containing the same amount
of DSP and with the same amount of crosslinking time,
the release time is increased as the amount of
glutaraldehyde is increased.
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Figure 1.

(a) Before Release
(b) After Release

(a)

(b)
Table 1.

The particle size distribution, synthesis efficiency and encapsulation efficiency of the microspheres are given.
Series

A (5%DSP;
0.5mL Glutaraldehyde; 30 min)
B (5%DSP;
0.5mL Glutaraldehyde; 60 min)
C (15%DSP;
0.5mL Glutaraldehyde; 30 min)
D (15%DSP;
0.5mL Glutaraldehyde; 60 min)
E (5%DSP;
0.75mL Glutaraldehyde; 30 min)
F (5%DSP;
0.75mL Glutaraldehyde; 60 min)
G (15%DSP;
0.75mL Glutaraldehyde; 30 min)
H (15%DSP;
0.75mL Glutaraldehyde; 60 min)

Synthesis Efficiency (%)

Particle size (µm)

Encapsulation Efficiency (%)

74.74

32.70

38.4

69.25

23.41

44.24

78.33

26.94

49.6

76.52

20.02

53.67

55.47

22.24

70.91

88.76

15.44

71.38

69.7

21.28

65.36

81.18

29.79

51.87
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Figure 2.
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